|
Characteristic
|
BCA cohort HER2-amplified BCA cohort
|
|---|
|
HER3-m (%)
|
p
|
HER3-c (%)
|
p
|
HER3-t (%)
|
p
|
HER3-m (%)
|
p
|
HER3-c (%)
|
p
|
HER3-t (%)
|
p
|
|---|
|
-
|
+
|
-
|
+
|
-
|
+
|
-
|
+
|
-
|
+
|
-
|
+
|
|---|
|
HER2 status
| | |
0.615
| | |
0.990
| | |
0.882
| | | | | | | | | |
|
Negative
|
85.8
|
83.8
| |
84.6
|
84.7
| |
84.2
|
84.9
| | | | | | | | | | |
|
Positive
|
14.2
|
16.2
| |
15.4
|
15.3
| |
15.8
|
15.1
| | | | | | | | | | |
|
Estrogen receptor status
| | |
0.057
| | |
0.280
| | |
0.839
| | |
0.013*
| | |
0.376
| | |
0.104
|
|
Negative
|
23.6
|
15.1
| |
30.8
|
18.7
| |
18.4
|
19.5
| |
54.3
|
31.7
| |
46.7
|
35.2
| |
46.5
|
32.8
| |
|
Positive
|
76.4
|
84.9
| |
69.2
|
81.3
| |
81.6
|
80.5
| |
45.7
|
68.3
| |
53.3
|
64.8
| |
53.5
|
67.2
| |
|
Progesterone receptor status
| | |
0.002**
| | |
0.368
| | |
0.443
| | |
0.888
| | |
0.882
| | |
0.716
|
|
Negative
|
43.2
|
26.4
| |
46.2
|
34.0
| |
38.2
|
33.3
| |
57.1
|
58.5
| |
60.0
|
58.0
| |
55.8
|
59.0
| |
|
Positive
|
56.8
|
73.6
| |
53.8
|
66.0
| |
61.8
|
66.7
| |
42.9
|
41.5
| |
40.0
|
42.0
| |
44.2
|
41.0
| |
|
Triple-negativity (HER2-/ER-/PR-)
| | |
0.000***
| | |
0.099
| | |
0.798
| | | | | | | | | |
|
No
|
83.8
|
96.2
| |
76.9
|
90.8
| |
89.5
|
90.5
| | | | | | | | | | |
|
Yes
|
16.2
|
3.8
| |
23.1
|
9.2
| |
10.5
|
9.5
| | | | | | | | | | |
|
Histological grade
| | |
0.121
| | |
0.855
| | |
0.705
| | |
0.435
| | |
0.767
| | |
0.956
|
|
I-II
|
72.8
|
81.4
| |
75.0
|
77.3
| |
75.4
|
77.8
| |
28.6
|
22.3
| |
26.7
|
23.3
| |
23.3
|
23.6
| |
|
III
|
27.2
|
18.6
| |
25.0
|
22.7
| |
24.6
|
22.2
| |
71.4
|
77.7
| |
73.3
|
76.7
| |
76.7
|
76.4
| |
|
Ki-67 proliferation index
| | |
0.597
| | |
0.985
| | |
0.852
| | |
0.475
| | |
0.213
| | |
0.658
|
|
Low
|
73.4
|
70.2
| |
71.4
|
71.7
| |
72.7
|
71.4
| |
22.9
|
17.6
| |
6.7
|
19.8
| |
20.9
|
17.9
| |
|
High
|
26.6
|
29.8
| |
28.6
|
28.3
| |
27.3
|
28.6
| |
77.1
|
82.4
| |
93.3
|
80.2
| |
79.1
|
82.1
| |
|
Histological type
| | |
0.629
| | |
0.359
| | |
0.204
| | |
0.055
| | |
0.940
| | |
0.960
|
|
Ductal
|
55.5
|
58.2
| |
69.2
|
56.4
| |
63.2
|
54.8
| |
85.3
|
94.8
| |
93.3
|
92.8
| |
92.7
|
92.9
| |
|
Lobular
|
44.5
|
41.8
| |
30.8
|
43.6
| |
36.8
|
45.2
| |
14.7
|
5.2
| |
6.7
|
7.2
| |
7.3
|
7.1
| |
|
Lymph nodal status
| | |
0.531
| | |
0.637
| | |
0.716
| | |
0.232
| | |
0.169
| | |
0.035*
|
|
Negative pN0
|
58.3
|
61.9
| |
66.7
|
59.9
| |
62.0
|
59.5
| |
65.7
|
54.5
| |
40.0
|
58.4
| |
42.9
|
61.4
| |
|
Positive pN+
|
41.7
|
38.1
| |
33.3
|
40.1
| |
38.0
|
40.5
| |
34.3
|
45.5
| |
60.0
|
41.6
| |
57.1
|
38.6
| |
|
Tumor size (TNM stage)
| | |
0.840
| | |
0.921
| | |
0.781
| | |
0.173
| | |
0.001***
| | |
0.368
|
|
pT1-pT2
|
91.9
|
91.3
| |
92.3
|
91.5
| |
90.8
|
91.8
| |
88.6
|
94.9
| |
73.3
|
95.5
| |
90.7
|
94.6
| |
|
pT3-pT4
|
8.1
|
8.7
| |
7.7
|
8.5
| |
9.2
|
8.2
| |
11.4
|
5.1
| |
26.7
|
4.5
| |
9.3
|
5.4
| |
|
Tumor size (cm)
| | |
0.003**
| | |
0.834
| | |
0.357
| | |
0.643
| | |
0.014*
| | |
0.143
|
|
<2cm
|
21.6
|
42.7
| |
28.6
|
32.4
| |
26.7
|
34.1
| |
51.7
|
46.9
| |
15.4
|
51.2
| |
37.1
|
51.4
| |
|
≥2cm
|
78.4
|
57.3
| |
71.4
|
67.6
| |
73.3
|
65.9
| |
48.3
|
53.1
| |
84.6
|
48.8
| |
62.9
|
48.6
| |
|
Patient age at diagnosis
| | |
0.726
| | |
0.624
| | |
0.217
| | |
0.069
| | |
0.000***
| | |
0.156
|
|
<50 years
|
21.6
|
20.0
| |
15.4
|
21.0
| |
15.8
|
22.4
| |
31.4
|
17.6
| |
60.0
|
16.7
| |
27.9
|
17.9
| |
|
≥50 years
|
78.4
|
80.0
| |
84.6
|
79.0
| |
84.2
|
77.6
| |
68.6
|
82.4
| |
40.0
|
83.3
| |
72.1
|
82.1
| |
|
Cytokeratin 5/14 expression
| | | | | | | | | | | |
0.583
| | |
0.561
| | |
0.006**
|
|
Negative
| | | | | | | | | |
85.3
|
88.7
| |
92.9
|
87.6
| |
76.2
|
92.0
| |
|
Positive
| | | | | | | | | |
14.7
|
11.3
| |
7.1
|
12.4
| |
23.8
|
8.0
| |
|
Basal phenotype (CK5/14+, ER-)
| | | | | | | | | | | |
0.191
| | |
0.801
| | |
0.001***
|
|
No
| | | | | | | | | |
85.3
|
92.5
| |
92.9
|
90.8
| |
78.6
|
95.2
| |
|
Yes
| | | | | | | | | |
14.7
|
7.5
| |
7.1
|
9.2
| |
21.4
|
4.8
| |
- p-values from Pearson’s Chi-Square test, statistically significant values are underlined and marked with symbols *p<0.05, **p≤0.01, and ***p≤0.001. Percentages of breast carcinomas presented according to membranous (−m), cytoplasmic (−c), and total (−t) HER3 expression; −/+ means low/high HER3 expression by IHC
